Description for medicine or protocol of treatment in detail:
|
1. Interventional method: All patients enrolled in this study received traditional TACE treatment, all of which were accessed through the right or left femoral artery under local anesthesia. Before chemoembolization, the feeding artery of the lesion was confirmed by arteriography, and then the feeding artery of the tumor was superselected by using a microcatheter. The chemoembolization process is a classic ''sandwich'' process, and the chemotherapeutic drugs, adriamycin and lipiodol mixture, and gelatin sponge particles are injected successively. The end point of embolization is the stagnation of blood flow in the tumor feeding artery. Finally, it was confirmed by hepatic arteriography that the tumor staining disappeared obviously, and there was no obvious blood flow in the tumor feeding artery.
2. Postoperative treatment
Control group: After receiving TACE treatment, appropriate rest and activities, eating easy-to-digest food, prohibiting smoking, drinking and taking related liver damage drugs, received conventional western medicine symptomatic treatment (physical cooling, pain relief, vomiting, liver protection, stomach protection, rehydration, etc.).
Treatment group: On the basis of the control group, they took Chaihu Huaji Prescription: Chaihu 30 grams, Scutellaria 9 grams, Pinellia 9 grams, ginseng 9 grams, Sanleng 10 grams, Curcuma lucidum 10 grams, Hematoxylin 6 grams, 9 grams of ginger, 10 grams of Cyperus officinalis, 6 grams of betel nut, 15 grams of citrus aurantium, 30 grams of pumice, and 30 grams of corrugated seeds. The above drugs are all decoction-free granules provided by the Chinese Medicine Pharmacy of Chongqing Hospital of Traditional Chinese Medicine. The usage is to take 150mL-200mL of boiled water every day, and take it twice with warm water half an hour after meals.
Course of treatment: The treatment cycle is 7 days.
|
Inclusion criteria
|
1. Those who meet the above-mentioned Western medicine diagnostic criteria for primary liver cancer and TCM syndrome differentiation;
2. Patients with CNLC stage Ib-IIIa;
3. Have not received any treatment for HCC, such as surgical resection, ablation, TACE, etc.;
4. Those who have good compliance, take medicine on time, review at the specified time, and have a cheerful personality;
5. Patients between the ages of 18 and 70;
6. The choice of embolic agent is ultra-liquefied lipiodol, and the dosage is determined according to the size of the tumor. The maximum amount of one administration does not exceed 20ml.
|
Exclusion criteria:
|
1. Combined with other systemic malignant tumors at the same time;
2. Serious adverse drug reactions;
3. Combined with severe complications of advanced decompensation of tumor and liver cirrhosis, such as upper gastrointestinal bleeding, hepatorenal syndrome, hepatic encephalopathy, etc.;
4. Those who are mentally ill or unable to cooperate;
5. There are absolute contraindications to TACE treatment;
6. Patients with severe heart disease, or kidney, brain, lung and hematopoietic system diseases;
7. The researcher believes that it is not suitable to participate in this clinical researcher.
|